Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SGX201

Small molecule · developed by Soligenix

Phase 1/2 Most advanced trial (none active)
SNGX Developer
1 Registered trials

What is SGX201?

SGX201 is delayed-release beclomethasone 17,21-dipropionate, a corticosteroid formulation. It is being studied in enteritis, with dosing given before the first radiation therapy session and continuing for 7 days after radiation therapy ends.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
beclomethasone 17,21-dipropionate, 17,-21 BDP
Drug type
Small molecule
Therapy area
Gastroenterology
Developer
Soligenix (SNGX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01073384 Phase 1/2 Enteritis Completed SNGX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Enteritis

More from Soligenix

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SNGX page.

Follow SNGX, the company behind SGX201

See SNGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNGX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.